Current vacancies – East and North Hertfordshire NHS Trust Are you a retired NHS employee? You could join the NHS Retirement Fellowship.

Want the opportunity to work at the forefront of RT #clinicaltrials? We are hiring!

Band 7 Clinical Scientist/Radiographer. 1-year post, renewable subject to funding:

www.enherts-tr.nhs.uk/careers/vaca...

Deadline 18th August.

DM for further information. #medphys #rtt #rtqa

Background: Despite extensive research efforts, glioblastoma (GBM) remains a deadly disease with poor prognosis. Although previous studies have identified various cell states within GBM tumors, the molecular mechanism underlying adaptive GBM cell plasticity induced by conventional therapy remains unclear. Methods: We used fluorescent reporters for proneural (PN) and mesenchymal (MES) subtypes to monitor GBM cell plasticity in real-time across multiple patient-derived cell lines. This approach revealed cells that concurrently expressed both proneural and mesenchymal markers. To investigate this unique hybrid population, we implemented a comprehensive methodological approach encompassing bulk and single-cell RNA sequencing, single-cell ChIP sequencing, nuclear proteomics, high-resolution imaging, orthotopic mouse models, clinical dataset analysis, and pharmacological and genetic techniques. This multifaceted strategy allowed us to gain functional and molecular insights into this distinct cellular population. Results: We showed that these hybrid cells are increased by conventional therapies, and are resistant to these therapies. At the molecular level, hybrid cells display significant alterations in chromatin structure and nuclear protein composition, elevated transcriptional activity, Myc activation, and improved transport between the nucleus and cytoplasm. Genetic and pharmaceutical inhibition of the nuclear import/export shuttling machinery, increased in hybrid cells, effectively suppressed adaptive GBM cell plasticity and hybrid identity, thereby enhancing the sensitivity of GBM cells to therapies. Conclusion: Our results indicate that GBM hybrid cells play a crucial role in chemoradiation resistance. The nuclear transport machinery presents a potential therapeutic target for hybrid cells, offering a way to counteract the typical resistance to treatment observed in GBM.

🧠 Why does glioblastoma always outsmart treatment? In our #Neuro-Oncology paper, we identified proneural-mesenchymal hybrid glioblastoma cells that are resistant to therapy and dependent on nuclear import. doi.org/10.1093/neuo...
Short walkthrough below. Let’s dive in! 🧵 (1/9)
#GBM, #BrainTumor

🎗️Today is #GlioblastomaAwarenessDay2025, designed to raise awareness of #glioblastoma, the most common primary brain cancer. At #EANO, we are dedicated to advancing scientific research, improving diagnostic tools, & developing therapies to combat this challenging disease. #GBMDay
👉 @braintumor.org

Are you looking to start your #lab in a fantastic scientific 🧪environment, with great colleagues, and in a spectacular place to live?

Then check out our open #junior #faculty position at the Department of Oncology, University of Lausanne, Switzerland:
www.unil.ch/dof/en/home/...

⏰ Deadline 27 June

Very interesting! Can you repost with the correct link? Thanks.

Reminder that #ctrad are holding a proposals guidance meeting on 11th July 2025.
We have a limited list of contacts to invite but if you are interested in UK radiation research we would love you to join us.
Please contact ctrad@macmillan.org.uk for details, register and submit a trial idea.

Read the latest perspective piece by @sueyom.bsky.social & Mary Helen Barcellos-Hoff in @natrevcancer.nature.com @ucsanfrancisco.bsky.social @ucsfhealth.bsky.social @ucsfcancer.bsky.social

Thank you Robert and MacMillan for reviving #CTRad - the most effective and impactful academic organisation I’ve ever been a part of. The future of #radiotherapy research in the UK is in safe hands.

Congratulations Mark!

We are pleased to annouce that a 3.5-year PhD position is available in the GDSC, for a project jointly supervised by Prof. Hochegger and Dr. Oliver. For additional details, inc. candidate eligibility, and how to apply:
www.sussex.ac.uk/study/fees-f...

📢 Reminder: Apply now to join the #EANO Nurse & Allied Healthcare Professional Committee (NAC)! Help shape EANO’s future & represent your field in the #NeuroOncology community.
🗓️ Deadline: May 31
🔗 bit.ly/45kRJyP
We look forward to meeting you!
@drflorienboele.bsky.social @karinpiil.bsky.social

PhD Studentship: Understanding and Targeting Cell Cycle Control in Cancer at University of Sussex At jobs.ac.uk, you can apply for a PhD Studentship: Understanding and Targeting Cell Cycle Control in Cancer. Explore our diverse range of PhD opportunities today.

Tony Oliver’s and my lab have a joint phd position available to investigate mitotic entry control mechanisms
Please forward to prospective students! Thank you

url.uk.m.mimecastprotect.com/s/ukMTCoy6DT...

Keir Starmer's EU Reset Deal Is the First Crack in the Brexit Wall Holding Britain Back This agreement marks the beginning of the end of the suffocating Brexit consensus that has gripped British politics for a decade, argues Adam Bienkov

“Starmer's EU deal is a big break in the suffocating Brexit consensus that has held Britain back for a decade. For the first time a UK government is doing things to actually undo the damage of Brexit, rather than increase it. For that alone it should be welcomed” 👏
bylinetimes.com/2025/05/19/k...

🧠New Neurology Fellowship Opportunity in London!

Join a cutting-edge Fellowship programme, designed to deepen your clinical expertise in the evolving field of neuro-oncology.

🔗Find out more here: www.tessajowellbraincancermission.org/news/tessa-j...

@nihr.bsky.social @kingshealth.bsky.social

Five major advances in anal and rectal cancer treatment with radiotherapy Rectal cancer is a type of bowel cancer that develops in the last several centimetres of the large intestine, just before the anus. It’s one of the most common cancers in Europe, with over 125,000 peo...

Five studies presented by experts including @montefiored.bsky.social from 🇬🇧 @universityofleeds.bsky.social / @leedsth.nhs.uk, 🇳🇱 @nkinl.bsky.social, and 🏴󠁧󠁢󠁳󠁣󠁴󠁿 @uofgcancersciences.bsky.social at #ESTRO25 showcase how #radiotherapy is reshaping treatments for anal and rectal #cancer.

Sorry I missed you Sue!

Or to put it another way, overseas students now subsidise the cost of teaching each UK undergraduate by an average of £2,500 each. Take them away and you've got an absolutely existential crisis for universities.

www.prospectmagazine.co.uk/politics/pol...

🔈 I am honored to be running alongside
Sunil Krishnan & David Yu
for Vice-President Elect of RRS
🙏🙏🙏

🧐You can find more info on the candidates here 👉
ftp.ameetingbydesign.com/ambddrop/202...

Vote by May 1️⃣3️⃣ radres.org/Login.aspx

@cvanpouillebox.bsky.social
@profajchalmers.bsky.social

Congratulations- fantastic result!

!!*RECRUITING*!!
We are looking for an enthusiastic PhD student @cruk-si.bsky.social @uofglasgow.bsky.social! This exciting fully funded project aims to unravel metabolic determinants of cachexia. Fancy some great teamwork with the labs of Owen Sansom and Campbell Roxburgh? Apply below!👇

HYPO-RT-PC 10 year data presented at #ESTRO2025. Seven fractions def non-inferior to 39 fractions, suggestion that 7 fractions might even be more likely to cure?

Clinical Lead, UK Collaborative for Cancer Clinical Research (UKCCCR) Salary: up to £21,000 for 0.2FTE Location: Hybrid working (home and office in central London, WC1)  Deadline: 8am, Monday 12th May 2025 Duration: one year fixed term (initially, with the expectation that the role will be renewed) Secondments welcome About the role AMRC has agreed to host the secretariat for a new UK Collaborative for Cancer Clinical Research (UKCCCR), which will be part of the Government’s Cancer Healthcare Goals Programme. A number of Cancer Clinical Research Groups (CRGs), each focusing on a specific cancer type or cross-cutting theme, bring together the cancer research community, to encourage strategic discussion and identify new areas of research. Many of the Secretariats for the CRGs are now run by AMRC member charities. The UKCCCR will provide a light touch secretariat to improve central coordination of these groups, allowing them to identify shared priorities, reduce duplication and be as effective as possible. The Clinical Lead will provide clinical expertise, advice and leadership on a consultancy basis to support UKCCCR and the programme manager. The role will require up to one day a week time commitment on a flexible basis. Please see the job description and person specification for full details.  How to apply Please read the job description and person specification. Please send your CV and a cover letter explaining what makes you a strong candidate for this role to jobs@amrc.org.uk. Please quote ‘UKCCCR Clinical Lead’ in the email subject.  If you have any questions about the role, or wish to have an informal conversation, please email jobs@amrc.org.uk.

Job alert: Clinical Lead wanted for the new UK Collaborative for Cancer Clinical Research (UKCCCR) – part of the Govt’s Cancer Healthcare Goals Programme.

💼 1 day/week (consultancy) | Hosted by
@amrc-uk.bsky.social  proudly supported by us.

Apply here 👉

Runcorn worn by 6 votes on a turnout of only 46.2% tells me two things:

Your vote is always important

Too many people think it isn’t

Spring and summer happened on the same day this year! #glasgow

Congratulations Jo - you will do a fantastic job!

Anthony Chalmers presents studies on combining radiation therapy and DNA damage response inhibitors, potential mechanisms and clinical implications.

#AACR25 | @profajchalmers.bsky.social

New episode of Simply Oncology coming for Head and Neck patients.
🎙️We speak to the superb @clairepaterson.bsky.social about radiotherapy and new treatments in H&N cancers.
🎙️A great resource for any patient undergoing H&N treatment
@simplyoncology.bsky.social

Best of luck Ane! And stay in touch with your UK friends 😍

Congratulations to the authors for completing this randomised study in an extremely rare cancer. Clear evidence of overall survival benefit from the addition of chemoradiation to standard of care. #radonc

How brilliant is this?! Well done Cassie for continually pushing the boundaries of what scientists can do.